Evidence map›Paper›PMID 41972004›Full record

ArticleiScience2026

RBM11 drives malignant progression of bladder cancer by regulating GNPDA1-PKM2 axis.

Hang Tong, Tinghao Li, Junlong Zhu, Qian Dou, Qiong Yu, Yan Sun, Weiyang He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hang TongDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Tinghao LiDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Junlong ZhuDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Qian DouDepartment of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Qiong YuDepartment of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Yan SunDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Weiyang HeDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the biological functions and molecular mechanisms of RNA-binding motif protein 11 (RBM11) in bladder cancer (BCa) progression. Integrated bioinformatics analysis of the TCGA database and validation in clinical tissues revealed that RBM11 is significantly upregulated in BCa and positively correlated with advanced tumor stage, poor prognosis, and epithelial-mesenchymal transition (EMT). RBM11 knockdown effectively suppressed migration, invasion, proliferation, and chemoresistance of BCa cells, whereas RBM11 overexpression produced opposite effects. Mechanistically, RBM11 promotes GNPDA1 expression by regulating alternative splicing of GNPDA. Furthermore, GNPDA1 directly interacts with PKM2 and inhibits its ubiquitin-proteasome-mediated degradation, thereby stabilizing PKM2 protein levels, enhancing glycolysis, and promoting malignant progression of BCa. Collectively, these findings indicate that RBM11 drives malignant progression of BCa through the GNPDA1-PKM2 axis, enhancing glucose metabolism reprogramming and EMT process, suggesting that RBM11 may be a potential therapeutic target for BCa.

Indexed as

cancercell biologymolecular physiology

Identifiers

PMID41972004
PMCPMC13068525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.